Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001753926-26-000789
Filing Date
2026-05-07
Accepted
2026-05-07 20:00:22
Documents
1
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 14045
  Complete submission text file 0001753926-26-000789.txt   15963
Mailing Address 140 BROADWAY 38TH FLOOR NEW YORK NY 10005
Business Address 874 WALKER ROAD SUITE C DOVER DE 19904 (646) 845-0040
3i, LP (Filed by) CIK: 0001841619 (see all company filings)

EIN.: 843800874 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 4020 STIRRUP CREEK DRIVE SUITE 110 DURHAM NC 27703
Business Address 4020 STIRRUP CREEK DRIVE SUITE 110 DURHAM NC 27703 919-908-2422
Pelthos Therapeutics Inc. (Subject) CIK: 0001919246 (see all company filings)

EIN.: 863335449 | State of Incorp.: NV | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-94460 | Film No.: 26955575
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)